RWLK REWALK ROBOTICS LTD

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of ReWalk Robotics Ltd. of a Class Action Lawsuit

The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of ReWalk Robotics Ltd. (“ReWalk”) (NASDAQGM:RWLK) pursuant to the Company’s initial public offering (“IPO”) on or around September 12, 2014.

You are hereby notified that a securities class action lawsuit has been commenced in the Superior Court of the State of California, County of San Mateo. If you purchased or otherwise acquired ReWalk securities pursuant to the initial public offering your rights may be affected by this action. To get more information go to:

http://zlk.9nl.com/rewalk-robotics-rwlk

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that while the Registration Statement filed pursuant to the IPO stated that the U.S. Food and Drug Administration had classified ReWalk as subject to special controls, including compliance with medical device consensus standards, performance of a postmarket surveillance clinical study demonstrating a reasonable assurance of safety and effectiveness in urban terrain, and a training program, among other things, the Company failed to disclose that it was unable to comply with the special controls. ReWalk also omitted that it had received a Warning Letter from the FDA in September of 2015, in which the FDA outlined ReWalk’s failures to propose and commence an adequate postmarket surveillance plan. On May 10, 2016, ReWalk revealed that at the time of the IPO, the company had been unable to comply with the FDA's special controls due to inadequate staffing.

If you suffered a loss in ReWalk and would like to obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/rewalk-robotics-rwlk.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
05/10/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on REWALK ROBOTICS LTD

 PRESS RELEASE

First Commercial Medicare Advantage Plan Provides Payment for ReWalk 7...

First Commercial Medicare Advantage Plan Provides Payment for ReWalk 7 Personal Exoskeleton Medicare Advantage claim processed in less than thirty days Additional progress with traditional Medicare claim approvals has accelerated timelines to payment in 2025 MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, announced today that it received its first payment from a commercia...

 PRESS RELEASE

Lifeward Achieves CE Mark Approval for the ReWalk 7 Personal Exoskelet...

Lifeward Achieves CE Mark Approval for the ReWalk 7 Personal Exoskeleton Seventh generation of industry-leading ReWalk Exoskeleton is now cleared for commercial launch in the European Union MARLBOROUGH, Mass. and YOKNEAM ILLIT, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, announced today that the company has received CE mark approval for the ReWalk 7 Personal Exoskeleton, clearing it for commercial sale in Europe....

 PRESS RELEASE

Lifeward Ltd. Reports Second Quarter 2025 Financial Results

Lifeward Ltd. Reports Second Quarter 2025 Financial Results Achieves record number of ReWalk systems placed for Medicare beneficiaries since fee schedule established Third consecutive quarter of U.S. ReWalk pipeline growth with over 130 qualified leads in process Appoints new CEO and CFO to spearhead strategic change and accelerate growth MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) --  Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations o...

 PRESS RELEASE

Lifeward Names Almog Adar as New CFO, Strengthening Executive Leadersh...

Lifeward Names Almog Adar as New CFO, Strengthening Executive Leadership MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Almog Adar, who previously served as the Company’s Vice President of Finance and Chief Accounting Officer, has been appointed as the Company’s new Chief Financial Officer. "I am thrilled to welcome Almog to the executive leadership t...

 PRESS RELEASE

Lifeward to Report Second Quarter Financial Results on August 14, 2025

Lifeward to Report Second Quarter Financial Results on August 14, 2025 MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its second quarter 2025 financial results before the markets open on Thursday, August 14, 2025. Mark Grant, President and Chief Executive Officer, and Almog Adar, Vice President of Finance, will host a conferen...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch